M-Insightlogo
  • Multiple Myeloma & MRD
    dropmenu
    What is Multiple Myeloma?
    MM is a blood cancer characterized by the clonal expansion of plasma cells in the bone marrow. Myeloma is rare, accounting for 1% of all cancers.
    dropmenu
    MM diagnosis and monitoring
    Multiple myeloma diagnosis and monitoring are based on clinical symptoms and a variety of laboratory tests. M-protein detection and quantification are integral parts of diagnosis and monitoring of MM.
    dropmenu
    What is MRD ?
    MRD stands for Minimal Residual Disease. It refers to the very small number of myeloma cells that are present in the bone marrow after treatment. These remaining cells often cannot be detected through traditional tests of treatment response. However, they have the potential to multiply and cause relapse.
  • M-inSight®
  • Resources
  • About us
    dropmenu
    Corgenix
    CAP/CLIA Clinical Laboratory: Precision disease monitoring tools powered by advanced proteomics and clinical excellence.
    dropmenu
    Sebia
    Center of Excellence for Research and Development: Our mission is to create advanced tools that translate complex biological signals from the patient’s body into clear, interpretable data.
  • Contact us
  • How to order?
    • Order M-inSight®
  • Multiple Myeloma & MRD
  • M-inSight®
  • Resources
  • About us
  • Contact us
  • How to order?
  • Order M-inSight®
  • Back
  • What is Multiple Myeloma?
  • MM diagnosis and monitoring
  • What is MRD ?
  • Back
  • Corgenix
  • Sebia

Catégorie: Articles

June 2023

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications – Front Oncol. 2022
June 2023

Extramedullary disease in multiple myeloma: a systematic literature review – Blood Cancer J. 2022
June 2023

Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure! – Journal of Clinical Oncology, 2022
June 2023

Mass spectrometry for the evaluation of monoclonal proteins in MM and related disorders – Blood Cancer J. 2021
  • Précédent
  • 1
  • 2
See what others can't
Order M-inSight®

Multiple Myeloma & MRD

Multiple Myeloma MRD Monitoring Diagnosis and Monitoring

M-inSight®

Discover M-inSight® Ordering information Resources Contact us
© 2026 M-inSight®
Terms of Use
Privacy policy
Privacy Practices
Claims presented in the website are supported by references on the Resources page.